These data emphasize the importance of sphingolipid metabolism in the presence of FH pathogenic variants, suggesting a potential role in the increased susceptibility to atherosclerosis observed in FH patients and highlighting SM as potential therapeutic targets to reduce CVD risk. This evidence concerns the gene FH and familial hyperaldosteronism.